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Abstract
Background: Traumatic brain injury (TBI) induces activation of microglia. Activated microglia can in turn increase
secondary injury and impair recovery. This innate immune response requires hours to days to become fully
manifest, thus providing a clinically relevant window of opportunity for therapeutic intervention. Microglial
activation is regulated in part by poly(ADP-ribose) polymerase-1 (PARP-1). Inhibition of PARP-1 activity suppresses
NF-kB-dependent gene transcription and thereby blocks several aspects of microglial activation. Here we evaluated
the efficacy of a PARP inhibitor, INO-1001, in suppressing microglial activation after cortical impact in the rat.
Methods: Rats were subjected to controlled cortical impact and subsequently treated with 10 mg/kg of INO-1001
(or vehicle alone) beginning 20 - 24 hours after the TBI. Brains were harvested at several time points for
histological evaluation of inflammation and neuronal survival, using markers for microglial activation (morphology
and CD11b expression), astrocyte activation (GFAP), and neuronal survival (NeuN). Rats were also evaluated at 8
weeks after TBI using measures of forelimb dexterity: the sticky tape test, cylinder test, and vermicelli test.
Results: Peak microglial and astrocyte activation was observed 5 to 7 days after this injury. INO-1001 significantly
reduced microglial activation in the peri-lesion cortex and ipsilateral hippocampus. No rebound inflammation was
observed in rats that were treated with INO-1001 or vehicle for 12 days followed by 4 days without drug. The
reduced inflammation was associated with increased neuronal survival in the peri-lesion cortex and improved
performance on tests of forelimb dexterity conducted 8 weeks after TBI.
Conclusions: Treatment with a PARP inhibitor for 12 days after TBI, with the first dose given as long as 20 hours
after injury, can reduce inflammation and improve histological and functional outcomes.
Keywords: Astrocyte, Behavioral, Forelimb, Inflammation, Microglia, Minocycline, Poly(ADP-ribose) polymerase, trau-
matic brain injury
Background
Microglia are the resident macrophages of the CNS [1].
Traumatic brain injury (TBI) leads to tissue disruption
and release of molecules from injured and dead cells
that elicit microglial and astrocyte activation [2,3]. Acti-
vated microglia change morphology, migrate to injury
sites, and release reactive oxygen species, nitric oxide,
cytokines, metalloproteinases, and other factors with
cytotoxic effects. Astrocytes similarly change morphol-
ogy and acquire a pro-inflammatory phenotype. While
this innate immune response can limit the effects of tis-
sue injury and infection, it can also impair recovery and
promote secondary neuronal death [1,4-7]. This
response requires hours to days to become fully mani-
fest after TBI, a time interval that provides opportunity
for therapeutic intervention. Conversely, some aspects of
the innate immune response can facilitate later tissue
repair and functional recovery [3,8]. Thus, the timing of
anti-inflammatory treatment may crucially affect
outcomes.
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Poly (ADP-ribose) polymerase-1 (PARP-1) is an
enzyme involved in both DNA repair and transcriptional
regulation [9,10]. PARP-1 is activated by DNA damage
and by cytokines such as TNFa. PARP-1 interaction
with NF-B regulates expression of several pro-inflam-
matory mediators, including proteases, iNOS, ICAM-1,
and TNFa [11-14]. PARP-1 activation has been identi-
fied in brain after TBI [15-17]. PARP-1 genetic defi-
ciency or enzymatic inhibition suppresses NF-kB-
dependent gene transcription in microglia [18] and pre-
vents their morphological transformation, proliferation
and migration to injury sites [4,13,19,20]. Several potent
PARP inhibitors are now available, and some have been
approved for clinical use. Of note, minocycline and
related tetracycline derivatives are also highly potent
PARP inhibitors [21], and these drugs are also potent
suppressers of microglial activation [22-24].
Prior studies have shown that PARP inhibition can
suppress inflammation and promote recovery when
given 18 - 24 hours after brain ischemia [25,26], but the
efficacy of this approach after TBI is not known. In the
present study we used a controlled cortical impact
model of TBI in the rat to determine whether delayed
treatment with a PARP inhibitor, INO-1001, would sup-
press microglial and astrocyte activation and improve
long-term recovery. INO-1001 was chosen for this study
because it is an extremely potent PARP inhibitor and it
has been approved for clinical trials [27].
Materials and methods
The studies were approved by the San Francisco Veter-
ans Affairs Medical Center Animal Care and Use Com-
mittee. Reagents were obtained from Sigma-Aldrich
except where noted. Male Sprague-Dawley rats (250-300
g; Simonsen Laboratories), were housed two per cage on
a 12 hour light/dark cycle with free access to food and
water.
Traumatic Brain Injury and drug treatment
A controlled cortical impact device (Pinpoint Precision
Cortical impactor, Hatteras Instruments, Cary, NC) was
used to produce a unilateral traumatic brain injury
(TBI). Rats were anesthetized with intraperitoneal injec-
tions of ketamine (80 mg/kg) plus xylazine (8 mg/kg)
and maintained at 37°C ± 0.5°C with a thermal mat
throughout the surgical procedure. The anesthetized
rats were placed in a stereotaxic frame with heads posi-
tioned to target the impact 3.5 mm left of bregma. A
midline scalp incision was made and a circular craniot-
omy was made while maintaining integrity of the dura.
Initial studies used a 2.5 mm diameter impactor pro-
grammed to 1.5 m/s velocity, 2.5 mm penetration depth,
and 120 ms dwell time. In a later study, used for long-
term behavioral endpoints, a 5 mm diameter impactor
was used and the penetration depth was increased to 5
mm. Following the cortical impact, the skin overlying
the site of injury was sutured closed and the animals
were maintained at 37°C for 30 minutes and observed
until recovered from anesthesia. Mortality rate was less
than 5%. Sham-operated controls were subjected to the
same surgical procedures except the cortical impact.
The PARP inhibitor INO-1001 (Inotek Pharmaceuticals,
Lexington, MA) was administered by intraperitoneal
injection at a dose of 10 mg/kg in 1.0 - 1.5 ml sterile
saline vehicle. Injections were begun 20 - 24 hours after
TBI surgery, and every 24 hours thereafter except where
otherwise noted.
Immunohistochemistry
Rats were deeply anesthetized with isoflurane, given
bilateral thoracotomy, and transcardially perfused with
saline followed by 4% formaldehyde. Brains were post-
fixed in 4% formaldehyde overnight at 4°C, cryopro-
tected in 20% sucrose for 2 days at 4°C, and rapidly
frozen in dry ice. Serial 40 μm coronal sections were
obtained using a cryostat. Four sets of 9 evenly spaced
(640 μm apart) sections spanning the injured cortex
were collected from each brain. Immunostaining was
performed using mouse monoclonal antibody to
CD11b (1:200, clone OX-42, Serotec, Oxford, UK), rab-
bit polyclonal antibody to glial fibrillary acidic protein
(GFAP; 1:1000, Chemicon), and mouse monoclonal
antibody to NeuN (1:1000, Chemicon). Incubations
were made in blocking buffer containing 1% albumin,
2% normal serum and 0.3% Triton X-100. Antibody
binding was imaged using fluorescent second antibo-
dies and confocal microscopy (Zeiss LSM 510) with
appropriated filter sets. For low magnification images,
CD11b antibody binding was visualized by the DAB
method [28], using biotin-conjugated second antibodies
and the Vectastain Elite ABC reagent (Vector Labora-
tories). Controls prepared with primary antibody
omitted showed no detectable fluorescence and mini-
mal background DAB staining under the conditions
employed.
Histological outcome measures
The TBI lesion cavity was defined on each section as the
area of brain devoid of NeuN staining (because both
astrocytes and microglia, but not neurons, grow and
move in to the lesion cavity). NeuN-stained sections
were photographed, and the perimeter of each hemi-
sphere was outlined using an image analysis program.
The area of each lesioned hemisphere was then sub-
tracted from the area of the contralateral hemisphere,
and these values were summed and multiplied by the
distance between sections to yield a lesion volume for
each brain (modified from [29].
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Activation of microglia and astrocytes was evaluated in
the lesioned and non-lesioned cortex and hippocampus
on 4 coronal sections spaced 640 μm apart and centered
on the lesion epicenter. Six 450 μm2 areas were photo-
graphed for later analysis: an area centered 625 um lat-
eral to the lesion edge and midway through the cortical
depth; the homologous contralateral cortex; and the hip-
pocampal dentate gyrus ipsilateral and contralateral to
the cortical lesion (Figure 1A). The edge of the lesion
was defined by complete lack of Neu N staining. The
regions analyzed were offset from the edge by 400 μM to
avoid introducing error by edge irregularities. Microglial
activation was scored by evaluating the density of CD11b
- positive microglia and microglial morphology (modified
from [25], as detailed in Table 1. Astrocyte activation was
quantified by measuring expression of glial fibrillary
acidic protein (GFAP). GFAP expression level in each
photographed area was calculated by multiplying the net
area of GFAP staining by the intensity of GFAP staining,
using the NIH ImageJ program.
Behavioral outcome measures
The behavioral studies were performed over a 2-week
interval beginning 8 weeks after TBI. Animals were
housed in a dedicated behavioral study facility during this
interval to minimize environmental changes associated
Figure 1 Time course of microglia and astrocyte activation in cortex after controlled cortical impact. (A) Diagram of coronal rat brain
section showing relationship of lesion cavity (red) to regions photographed (black squares). (B) Confocal fluorescence images of CD11b
immunoreactivity (red) in peri-lesion cortex at designated time points after TBI. Panel ‘7d mag’ is a magnified view showing amoeboid
morphology of the activated microglia (arrows). (C) Quantification of microglial activation. (D) Astrocytes are immunostained for GFAP (green),
and staining is quantified in (E). Scale bars are 20 μm. n = 3 at each time point; * p < 0.05, ** p < 0.01 vs. sham.
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with transfer between home cage and the testing arenas.
All tests were performed and analyzed by individuals
blinded to the experimental conditions. For the cylinder
test, rats were placed in a clear plexiglass cylinder as
described previously [30]. Normal rats touch the walls
equally often with each forelimb, but hemi-paretic rats
touch the walls less often with the affected limb. Rats were
kept in the cylinder for 10 minutes and videotaped for
scoring at a later date. The number of wall touches with
each forelimb was scored for each rat. For the sticky tape
test, a 0.5-inch diameter round adhesive tape was placed
on the heel of each forepaw. The time to remove the tape
from each paw was measured. Five trials were performed
and the median value was calculated for each rat. Indivi-
dual trials were timed out at 10 minutes. For the vermicelli
test, rats were food-restricted for 48 hours and then given
5 pieces of dry vermicelli, each 7-cm in length, in their
home cages as described previously [31]. Manipulation of
the vermicelli was videotaped for later analysis. Normal,
typical handling behavior involves holding the noodle
asymmetrically with 2 paws, one as the guide paw and the
other as the grasp paw, with the paws apart until the noo-
dle is less than 3.5 cm in length. The behaviors scored on
the videotapes were as follows: 1) Paws apart (a normal
behavior) - paws placed assymetrically and apart with each
adjustment; 2) Uses mouth (abnormal) - mouth is used to
pull the noodle through the forepaws; 3) Single paw use
(abnormal) - only one paw is used to manipulate the
pasta; 3) Drop (abnormal) - the noodle is dropped shortly
after eating begins; 4) Head tilt (abnormal) - head is tilted
or face lowered while eating the noodle. The “hands apart”
scoring was normalized to the number of total adjust-
ments. The other measures were scored with a 1 if exhib-
ited and a 0 if not for each of the five noodles consumed,
and summed for each specified behavior. Rats were also
scored for the total number of pauses counted while eat-
ing, the total number of paw adjustments made while eat-
ing, and the total time taken to consume the 5 noodles.
Data analysis
Outcome measures were evaluated by observers blinded
to experimental conditions. Results are presented as
mean ± standard error. Statistical analyses were done by
ANOVA followed by the Bonferroni test where compar-
isons were made between multiple groups or Dunnet’s
test where multiple groups were compared against a
common control group. Composite scores for the vermi-
celli test data were obtained after first normalizing the
score for each animal in each individual test to the
mean score of the TBI + vehicle treatment group of that
test.
Results
Time course of brain inflammation after TBI
The controlled cortical impact produced a necrotic lesion
in the dorsal cortex that extended from the cortical sur-
face to the deeper cortical layers, but not to the underly-
ing corpus callosum (Figure 1A). We first evaluated the
time course of microglia and astrocyte activation in the
peri-lesion cortex and ipsilateral hippocampus after this
injury to identify the period of peak inflammation. Acti-
vated microglia increase expression of the integrin
CD11b and acquire an “amoeboid” morphology, with
retracted, thickened processes and enlarged soma [1].
Activated astrocytes (also termed “reactive astrocytes”)
increase expression of GFAP and, like activated micro-
glia, also exhibit retraction of processes and enlarged
soma [32]. In peri-lesion cortex, activation of microglia
and astrocytes peaked at about day 7 (Figure 1). There
was no detectable activation in the contralateral cortex or
in ipsilateral cortex remote from the impact site (not
shown). In the ipsilateral hippocampus (dentate gyrus),
microglial and astrocyte activation peaked by 5 days after
TBI (Figure 2). Similar but less extensive activation was
observed in the contralateral hippocampus (not shown).
Post-treatment with INO-1001suppresses microglial
activation after TBI
Separate groups of rats were then treated with INO-1001
(10 mg/kg) or vehicle for 7 days (encompassing the time
of peak inflammation) to confirm that PARP inhibition
can suppress TBI-induced brain inflammation. The drug
was administered daily, with the first dose given 20 - 24
hours after injury. As expected, treatment initiated at this
delayed time point did not affect the size of the necrotic
lesion (not shown). However, rats receiving INO-1001
did exhibit reduced microglia activation in the peri-lesion
cortex (Figure 3A,B,C). There was also a significant
reduction in microglial activation in the ipsilateral hippo-
campus (Figure 3D,E). Reductions in astrocyte GFAP
expression did not achieve statistical significance.
No rebound inflammation after stopping treatment with
PARP inhibitor
We next considered the possibility that INO-1001 might
induce a “rebound” inflammation when discontinued




(cells per 450 μm2)
Score
none 0 0-25 0
1-10% 1 25-50 1
10-25% 2 50-100 2
25-50% 3 100-150 3
> 50% 4 > 150 4
Microglia were identified by CD11b immunoreactivity. Scoring with the two
criteria were combined to yield an aggregate microglia activation score (0-8).
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after the peak interval of microglial activation. One
group of rats was treated with INO-1001 (or vehicle) for
12 days following TBI, at which time microglial activa-
tion had largely waned. A second group of rats was trea-
ted with INO-1001 (or vehicle) for 12 days, followed by
4 days of no treatment before brain harvest. The four-
day interval was chosen because this interval is long
enough to observe rebound inflammation when it
occurs in other settings [33-36]. INO-1001 was in all
cases initiated 20-24 hours after TBI. Results of these
studies showed no rebound increase in microglial or
astrocyte activation, in either cortex or hippocampus,
following cessation of INO-1001 treatment (Figure 4).
Improved neuronal survival in the peri-lesional cortex
Microglial activation can lead to neuronal death [1,4,5].
We therefore evaluated neuronal survival in the peri-
lesion cortex in the same brains evaluated for rebound
inflammation. Neuronal density was found to be
decreased in peri-lesion cortex relative to density in the
contralateral (non-injured) cortex, and this decrease was
attenuated in rats treated with INO-1001 (Figure 5).
Effects of INO-1001 on long-term behavioral outcome
measures
Studies using the initial TBI protocol showed no detect-
able forelimb dysfunction at the 8 week post-injury time
point (data not shown). Consequently, a second study
was performed using increased impactor depth and
dwell time. Rats were subjected to either TBI or sham
TBI, and treated with either vehicle or INO-1001 on
post-surgery days 1 through 13 (12 days of treatment).
Forelimb dexterity was evaluated 8 weeks after TBI
using the cylinder test, the sticky tape test, and the ver-
micelli test. The cylinder test again showed no effect of
TBI on paw preference (not shown). However, the sticky
Figure 2 Time course of microglia and astrocyte activation in the hippocampus after controlled cortical impact. (A) Confocal
immunofluorescence staining for activated microglia (CD11b) in the ipsilateral hippocampal dentate gyrus at designated time points after TBI.
Panel ‘1d mag’ is a magnified view showing amoeboid morphology of activated microglia (arrows). (B) Quantification of microglial activation. (C)
Astrocytes are immunostained for GFAP (green), and staining is quantified in (D). Scale bars are 20 μm. n = 3 at each time point; * p < 0.05, ** p
< 0.01 vs. sham.
d’Avila et al. Journal of Neuroinflammation 2012, 9:31
http://www.jneuroinflammation.com/content/9/1/31
Page 5 of 11
tape test showed a large increase in time taken to
remove tape applied to the right forepaw in the TBI
rats, and this increase was significantly attenuated in
rats treated with INO-100 (Figure 6A). Similarly, the
vermicelli test, which is sensitive to deficits in fine coor-
dination of the forepaws, showed abnormalities in sev-
eral parameters in the TBI rats, and these were also
attenuated by INO-1001 treatment (Figure 6B). Other
parameters of the vermicelli test evaluated (head tilt,
single paw use, and total feeding time, and total number
of pauses) showed no significant difference between TBI
and sham surgery groups and were therefore not
included in the composite score analysis. Evaluation of
the brains after behavioral testing (11 weeks after TBI)
showed lesion cavity size to be not significantly different
in the vehicle and INO-treated groups; 39.7 ± 3.1 and
43.7 ± 1.8 mm3, respectively.
Discussion
The time course studies presented here showed that
activation of both microglia and astrocytes peaked
between 5 and 7 days after TBI in the peri-lesion cortex,
Figure 3 Post-injury treatment with INO-1001 reduces microglia and astrocyte activation. (A) Coronal rat brain sections showing
microglial activation (CD11b immunostaining, brown) around the lesion sits. Rats were treated with vehicle or INO-1001 beginning 1 day after
TBI, and brains were harvested at day 7. (B) Higher power confocal immunofluorescence staining of microglia (CD11b, red) and astrocytes (GFAP,
green) in the peri-lesion cortex of rats treated with INO-1001 or vehicle. (C) Quantification of immunofluorescence. (D) Immunostaining in the
ipsilateral hippocampal dentate gyrus of rats treated with INO-1001 or vehicle at day 7 post-TBI. (E) Quantifications of immunostaining in
ipsilateral hippocampus. Scale bars are 20 μm. n = 3; *P < 0.05, **P < 0.01.
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and remained evident beyond 2 weeks. These observa-
tions are similar to those of prior reports [37,38]. This
inflammatory response was suppressed by the PARP
inhibitor, INO-1001. The reduced inflammation was
accompanied by improved neuronal survival near the
impact site and by improved performance on measures
of forelimb dexterity carried out 8 weeks after injury.
Importantly, treatment with the PARP inhibitor was not
begun until 20 - 24 hours after TBI, a time window rele-
vant to clinical treatment settings.
Neuronal death has been observed as a delayed effect
of TBI [39,40]. Here, the neuronal loss co-localized with
microglial activation, and both microglia activation and
the neuronal loss were suppressed by INO-1001. This
result, along with the known cytotoxicity of acutely acti-
vate microglia, suggests that the INO-1001 preserved
neuronal survival by suppressing microglial activation;
however, other potential mechanisms cannot be
excluded.
One such potential mechanism is direct neuroprotec-
tion by INO-1001. Independent of its anti-inflammatory
actions, INO-1001 and other PARP inhibitors can inter-
rupt a programmed cell death pathway that is triggered
by DNA damage [41-43]. Accordingly, prior studies have
shown salutary effects of PARP inhibitors given shortly
(within 60 minutes) after TBI [16,44-47]. A key and novel
aspect of the present study is that PARP inhibition was
not initiated until 20 - 24 hours after TBI. There were
two reasons for this treatment delay. First, we were striv-
ing to identify a treatment approach that can be effective
when initiated at time points relevant to clinical settings,
which is generally several hours after injury. Second, we
Figure 4 No rebound inflammation after INO-1001 is discontinued. Rats were treated with INO-1001 (or vehicle) beginning 1 day after TBI
in one of two regimens: i) for 12 days, then euthanized, or ii) for 12 days followed by 4 days without treatment. (A) Confocal immunostaining of
microglia (CD11b) and astrocytes (GFAP) in peri-lesion cortex. (B) Quantification shows no significant increase in microglial or astrocyte activation
after stopping INO-1001. (C) Confocal immunostaining of microglia and astrocytes in the ipsilateral hippocampus dentate gyrus. (D)
Quantification shows no increase in microglial or astrocyte activation after stopping INO-1001. Bars represents 20 μm. n = 4-5; *P < 0.05, **P <
0.01 vs. vehicle treatment.
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aimed to specifically test the idea that suppressing
inflammation would improve outcome. A cyoprotective
effect of acute PARP inhibition would confound testing
of this idea because a reduction in initial injury severity
would reduce injury-induced inflammation, independent
of a direct anti-inflammatory effect. We cannot be abso-
lutely certain that INO-1001 had no cytoprotective
effects when administered 20 hours after injury, but this
is rendered unlikely by the lack of an effect on necrotic
lesion size in INO-1001 - treated groups, and by the lack
of literature precedent for a cytoprotective effect of
PARP inhibitors beyond 3 hours after injury.
Figure 5 Neuronal density in the peri-lesion area. (A)
Immunostaining for neurons (NeuN) in brain sections from rats
treated as described in Fig. 4. The black and yellow rectangles in
the low power views (left) show the regions magnified in the high
power views (right). Cell counts were made in the regions identified
in the yellow rectangle, 400 μm lateral to the lesion cavity edge,
and in the homologous cortex of the contralateral hemisphere (not
shown). Scale bars are 400 μm (low power views) and 40 μm (high
power views). (B) Neuronal density was expressed in each animal as
the ratio of densities in the lesioned and non-lesioned hemispheres.
n = 4-5; *P < 0.05 vs. vehicle.
Figure 6 Effect of INO-1001 treatment on forelimb dexterity.
Rats were subjected to TBI or sham surgery, and were treated with
INO-1001 or vehicle for 12 days beginning 1 day after surgery.
Behavioral assessments were made 8 weeks after TBI. (A) Time to
remove an adhesive tape from the contralateal forelimb was
markedly increased by TBI, and this time was reduced in the
animals treated with INO-1001. n = 6-9; *P < 0.05. (B) Scoring of
vermicelli test results. n = 6-9. *P < 0.05, P **P < 0.01, #P < 0.05 vs.
sham, vehicle-treated.
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In addition to neurotoxic effects, microglial activation
can also have beneficial effects on outcome. The effects
of microglial activation depend on the nature of the
inciting stimulus, microglial heterogeneity, and other
factors [3,8,48]. Temporal aspects of microglial activa-
tion may be particularly important, because initial
microglia activation appears to be suited for stopping
infection, while later activation and infiltration of blood-
derived macrophages promotes repair and regeneration
[8,49]. Thus, short periods of immunosuppression could,
in principle, prevent the cytotoxicity associated with
acute microglial activation without impairing the long-
term beneficial effects of microglia activation on neurite
outgrowth, remodeling, and functional recovery. This
temporal consideration was a rationale for the 12 day
treatment period employed here. This treatment period
was based on the observation that the acute inflamma-
tory response begins to wane after day 7 in this TBI
model. We also considered the possibility that there
may be a “rebound” in inflammation at the time of drug
treatment ended, and that this rebound could negate
any beneficial effects of limited immunosuppression.
However, we found no evidence of a rebound effect on
either astrocytes or microglial activation.
A technical limitation of this study is that there is no
direct measure of PARP activity in the injured brains.
PARP activity can be measured acutely after TBI by the
accumulation of poly(ADP-ribose) polymer, the enzy-
matic produced of PARP-1 and other PARP species
[15-17]. However, the polymer is quickly degraded by
poly(ADP-ribose) glycohydrolase (PARG), such that
polymer accumulation occurs only during the relatively
transient post-injury interval when increased PARP
activity has not yet been matched by increased PARG
activity [9,13,14,26,43]. The inference here that the anti-
inflammatory effects of INO-1001 result from a reduc-
tion in PARP activity that is otherwise be elevated for
several days after TBI is based on the prior observations
that TBI induces PARP activation [15-17], the high
potency and selectivity of INO-1001 as a PARP inhibitor
[16,27,45], and the ability of PARP inhibitors to block
NF-kB - mediated inflammatory responses
[12-14,20,25,26]. Nevertheless, the results presented can-
not exclude the possibility that the anti-inflammatory
effects of INO-1001 result from some other, unrecog-
nized action of this drug.
Astrocyte activation is an important feature of glial
scar formation during acute brain inflammation, but
chronic astrogliosis may be deleterious to axonal regen-
eration after CNS injury [7]. The stimuli triggering
astrocyte activation in TBI have not been identified, and
it may be that astrocyte activation is driven at least in
part by factors released from microglia. In the present
studies, INO-1001 was found to significantly reduce
astrocyte activation in some, but not all, of the experi-
mental conditions examined. The reasons for this varia-
bility is not clear, but it suggests that astrocyte
activation is not entirely dependent upon microglial
activation and that astrocyte activation is regulated at
least in part by PARP-1 - independent mechanisms.
Importantly, the histological effects of INO-1001
administration were accompanied by improvements in
tests of forelimb dexterity. These tests were done 8
weeks after TBI, indicating a long-lasting drug effect.
We speculate that only tests of fine forelimb dexterity
are capable of identifying functional deficits at this late
time point, given that the cylinder test, which evaluates
proximal limb function, showed no abnormalities. The
improved forelimb dexterity may be attributable to
improved neuronal survival in the peri-lesion area, but
other explanations are also possible. In particular,
these studies did not evaluate effects of the PARP inhi-
bitor of diffuse axonal injury or axonal survival after
TBI.
Conclusions
These findings support the idea that suppressing the
innate brain inflammatory response during the first few
days after TBI can improve histological and functional
outcomes. Effective suppression of the inflammatory
response can be achieved with a PARP inhibitor, and
with a delay in treatment onset of 20-24 hours after
TBI.
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